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Our understanding of the G protein-coupled receptor (GPCR) family of cell surface receptors 
continues to advance at a pace. Driven by a flow of new atomic level structures and novel 
insights into receptor signal transduction, we are learning more of the fundamental biology 
of this therapeutically important class of receptors. In this Special Edition of ACS 
Pharmacology and Translational Sciences we have attempted to capture some of these 
advances in a mixture of articles that includes reviews, original research papers, a perspective 
and the outcome of a workshop.  
 
Not surprisingly a number of articles have focused on the question of ligand bias or functional 
selectivity. Understanding the rules that govern the rational-design of GPCR ligands that drive 
receptor signalling towards pathways that promote clinical efficacy and away from pathways 
that mediate toxicity/adverse outcomes has been the aim of many of the world’s leading 
GPCR research groups1-5. Here the challenges of the identification and characterisation of 
biased ligands is exemplified in an article by Wouters et al. who focus on the cannabinoid CB1 
receptor to discover novel biased ligands.  The mechanism of bias signalling is an area of 
intense investigation and is covered here in an article by Verweij et al., where the role played 
by receptor phosphorylation in driving differential signalling is considered using the histamine 
H4 receptor as an exemplar. It is now clear that mechanisms other than those centred on 
receptor phosphorylation6 and arrestin interaction7 may underlie bias signalling, a point made 
clearly in the article by van der Velden et al., where ligand binding kinetics is considered not 
only in the context of functional selectivity but also as an important contributing factor to in 
vivo efficacy of class A GPCR ligands. van der Velden also touches on the importance of 
signalling not from the membrane but from endosomal compartments a topic expanded on 
in a review article by Plouffe et al. In this contribution Plouffe et al. not only provide an update 
on the latest advances in our understanding of GPCR signalling from intracellular 
compartments, but importantly places this process in a physiological and pathophysiological 
context by focusing on the importance of intracellular compartmental signalling in cardiac 
function.  
 
The Plouffe article is just one of a number of contributions that draws a link between 
molecular pharmacology and translational science. Prominent among these is an article by 
Abd-Elrahman et al. where they present evidence that the Type 5 metabotropic glutamate 
receptor (mGluR5), contributes to the pathology of Alzheimer’s disease. The translational 
theme is also taken up by Eiden et al. in a slightly different contribution summarising the 
outcome of a workshop that draw together the world’s experts in peptide-liganded receptors 
asking what are the best receptor classes and strategies to target peptide-liganded receptors 
in the treatment of neurological and psychiatric disorders? Among the most relevant areas of 
translational research in the GPCR field is that of the role of GPCRs in inflammation. Here the 
review article by Dahlgren et al. addresses the role of GPCRs in neutrophil biology and how 
allosteric modulators and biased ligands targeting neutrophil GPCRs might offer novel 
therapeutic approaches to the control of inflammation. 
 
Where would a special edition focused on GPCRs be without an article on atomic structure? 
In a contribution from Liang et al., cryo-electron microscopy structures provide an atomic 
level understanding of ligand specificity of the calcitonin receptor-like receptor (CLR). This 
receptor, when dimerised with its chaperon protein RAMP-1, generates the calcitonin gene-
related peptide receptor (CGRP), whereas dimerization with RAMP2 and RAMP3 results in the 
adrenomedullin receptors 1 and 2, respectively. The paper by Liang et al. provides an 
explanation behind the allosteric modulation of CLR by the RAMP-family. Staying with this 
class B receptor family Garelja et al. investigate the mechanism of differential signalling of 
CLR when dimerised with RAMP1, 2 and 3 and in a separate contribution Gingell et al. 
describes how CLR dimerization with different RAMP proteins promotes different 
mechanisms of receptor internalisation. Continuing with the theme of Class B receptors Fang 
et al. provide a mechanistic understanding of the internalisation of the glucagon-like peptide-
1 receptor.  
 
Finally, our Special Edition presents a series of articles demonstrating the importance of novel 
post-translational modifications. Goth et al. reviews the area of post translational 
modification of extracellular domains on GPCRs. This includes the importance of 
glycosylation, tyrosine sulphation, modification of proteolytic cleavage sites and extracellular 
sites of phosphorylation. The importance of extracellular post-translational modifications is 
expanded on further in the contribution by Marullo et al. where they review the role of N-
glycan chains located at the N-terminus of GPCRs that act as mechano-sensors playing a role 
in cell:cell interactions that can provide a means of mechanical activation of GPCRs. 
 
This special edition has drawn a number of contributions from the newly established 
European network of scientists drawn together under the banner of the European Network 
on Signal Transduction (ERNEST). This exciting collaborative network that brings together 
scientists from within the European Union and also associated countries to tackle unresolved 
questions in GPCR signal transduction and biology. The aims, objectives and work packages 
of ERNEST are presented in an article by Sommer et al. 
 
Overall, we hope that you find this special edition both informative and enjoyable. 
 
Andrew B. Tobin  
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